Sfoglia per AUTORE
REDA G
Collezione AO Cuneo

  

Items : 33

Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study. in Hematological oncology / Hematol Oncol. 2024 Jan;42(1):e3216. doi: 10.1002/hon.3216. Epub 2023 Sep 29.

2024
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Molica S; Malgieri S; Iannella E; Caira M; Finsinger P; Gualberti G; Reda G; Gozzetti A; Coscia M; Vallisa D; Pane F; Cuneo A; Albano F; Zamprogna G; Mauro FR; Trentin L; Albi E; Sportoletti P; Gaidano G; Laurenti L; Chiarenza A;

Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. in American journal of hematology / Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29.

2023
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria

Trentin L; Cuneo A; Foà R; Ghia P; Coscia M; Laurenti L; Molica S; Zatta I; Cavarretta CA; Angotzi F; Cellini A; Ruocco V; Rigolin GM; Sportoletti P; Trimarco V; Murru R; Marchetti M; Pietrasanta D; Cibien F; Vitale C; Sanna A; Derenzini E; Proietti G; Ferrarini I; Reda G; Mauro FR; Scarfò L; Gentile M; Farina L; et alii...

Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):201-204. doi: 10.1002/hon.3047. Epub 2022 Aug 19.

2023
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Novara

Marasca R; Foà R; Ballotta L; Moia R; Cuneo A; Chiurazzi F; Reda G; Gottardi D; Orsucci L; Maccaferri M; De Paoli L;

Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. in American journal of hematology / Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.

2023
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Levi S; Trentin L; Foà R; Cuneo A; Herishanu Y; Gentile M; Perry C; Gattei V; Gaidano G; Rossi D; Neri A; Olivieri J; Bomben R; Zucchetto A; Visentin A; Loseto G; Pietrasanta D; Chiarenza A; Braester A; Murru R; Aviv A; Varettoni M; Coscia M; Tadmor T; Shvidel L; Sportoletti P; Laurenti L; Reda G; Ruchlemer R; et alii...

Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study. in Hematological oncology / Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1.

2023
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria

Laurenti L; Cuneo A; Foà R; Trentin L; Coscia M; Rigolin GM; Mattiello V; Gattei V; Sportoletti P; Scortechini I; Moia R; Gentile M; Catania G; Loseto G; Chiurazzi F; Malerba L; De Paolis MR; Angeletti I; Ferrari A; Giordano A; Baratè C; Quaresmini G; Leone MMA; Farina L; Fresa A; Piciocchi A; Vitale C; Reda G; Visentin A; et alii...

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara

Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R; Guarini A; Nanni M; Neri A; De Propris MS; De Novi LA; Visentin A; Vitale C; Albano F; Molinari MC; Pietrasanta D; Mattiello V; Liberati AM; Giordano A; Gottardi D; Patrizi VB; Galieni P; Musuraca G; Deodato M; Arcari A; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study. in Leukemia / Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18.

2023
AO Cuneo

Gattei V; Del Poeta G; Foà R; Di Raimondo F; Tafuri A; Zaja F; Fronza G; Morabito F; Gentile M; Cuneo A; Del Principe MI; Postorino M; Laureana R; Olivieri J; Chiarenza A; Reda G; Laurenti L; Marasca R; Bulian P; Degan M; Polesel J; Tissino E; Pozzo F; Zucchetto A; Papotti R; Vit F; Bittolo T; Rossi FM; Bomben R; et alii...

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. in American journal of hematology / Am J Hematol. 2022 May;97(5):E176-E180. doi: 10.1002/ajh.26502. Epub 2022 Feb 25.

2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara

Mauro FR; Trentin L; Foa' R; Tedeschi A; Gaidano G; Cuneo A; Coscia M; Guarente V; Noto A; Ielo C; Deodato M; Del Poeta G; Stelitano C; Moia R; Giordano A; Levato L; Rigolin GM; Gentile M; Murru R; De Paoli L; Laurenti L; Vitale C; Ciolli S; Chiarenza A; Sportoletti P; Frustaci AM; Visentin A; Reda G; Giannarelli D; et alii...

Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. in American journal of hematology / Am J Hematol. 2022 Mar 1;97(3):E95-E99. doi: 10.1002/ajh.26437. Epub 2021 Dec 21.

2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Alessandria

Cuneo A; Trentin L; Foà R; Molica S; Laurenti L; Pravato S; Marchetti M; Murru R; Gentile M; Rigolin GM; Quaglia FM; Coscia M; Piazza F; Reda G; Fresa A; Ciolli S; Scarfò L; Sportoletti P; Pietrasanta D; Vitale C; Mauro FR; Cibien F; Visentin A;

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. in Haematologica / Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325.

2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara

Cuneo A; Laurenti L; Ghia P; Foà R; Trentin L; Pompili M; Tedeschi A; Mauro FR; Del Poeta G; Scarfò L; Autore F; Tomasso A; Di Sevo D; Arena V; Deodato M; Ielo C; Frustaci AM; Piciocchi A; Rughini A; Cassin R; Albano F; Quaglia FM; Pennese E; Moia R; Gentile M; Murru R; Motta M; Coscia M; Visentin A; et alii...

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. in Journal of hematology & oncology / J Hematol Oncol. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.

2022
AO Cuneo
ASL Vercelli
ASL Cuneo 1
AOU Alessandria

Ghia P; Stamatopoulos K; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Cuneo A; Carrier M; Wróbel T; Segundo LYS; Visentin A; Vitale C; Vukovic V; Wasik-Szczepanek E; Tomic K; Tonino S; Trentin L; Van Der Spek E; van Gelder M; Varettoni M; Shrestha A; Šimkovi? M; Smirnova S; Špa?ek M; Sportoletti P; Stanca O; Stavroyianni N; Te Raa D; et alii...

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. in Leukemia & lymphoma / Leuk Lymphoma. 2022 Aug;63(8):1985-1988. doi: 10.1080/10428194.2022.2053532. Epub 2022 Mar 27.

2022
AO Cuneo
AOU Città della Salute di Torino

Tedeschi A; Ferrario A; Montillo M; Zamprogna G; Marinoni S; Tani M; Ferrarini I; Borella C; Varettoni M; Ibatici A; Motta M; Sanna A; Massaia M; Orsucci L; Quaresmini G; Vanazzi A; Vitale C; Reda G; Mauro FR; Laurenti L; Murru R; Visentin A; Frustaci AM; Sportoletti P; Deodato M;

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study. in Frontiers in oncology / Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022.

2022
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria

Laurenti L; Trentin L; Cuneo A; Foà R; Ghia P; Coscia M; Reda G; Scarfò L; Angotzi F; Cellini A; Pravato S; Molica S; Marchetti M; Murru R; Gozzetti A; Gentile M; Rigolin GM; Quaglia FM; Sanna A; Sportoletti P; Cibien F; Mattiello V; Mauro FR; Catania G; Fresa A; Vitale C; Visentin A;

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.

2021
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara

Foà R; Chiarenza A; Penna G; Gottardi D; Derenzini E; Levato L; Orsucci L; Gattei V; Gentile M; Sanna A; Gozzetti A; Olivieri J; Murru R; Baratè C; Leone M; Stefoni V; Malerba L; Ibatici A; Tisi MC; Marasca R; Chiurazzi F; Varettoni M; Farina L; Del Poeta G; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; et alii...

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Foà R; Ferrarini M; Polliack A; Gaidano G; Trentin L; Cuneo A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Neri A; Bomben R; Biagi A; Del Giudice I; Angeletti I; Galimberti S; Rago A; Caracciolo D; Cassin R; D'Arrigo G; Mendicino F; Botta C; Martino EA; Vigna E; Zucchetto A; Rossi FM; Scortechini I; et alii...

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. in Cancers / Cancers (Basel). 2021 Jun 29;13(13):3240. doi: 10.3390/cancers13133240.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Trentin L; Gentile G; Girmenia C; Martelli M; Gaidano G; Foà R; Cuneo A; Tedeschi A; Molica S; Coscia M; Noto A; Guarente V; Stelitano C; Del Poeta G; Giordano A; Rigolin GM; De Paoli L; Murru R; Gentile M; Levato L; Ielo C; Laurenti L; Ciolli S; Vitale C; Frustaci AM; Chiarenza A; Sportoletti P; Reda G; Visentin A; et alii...

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. in Blood / Blood. 2021 Jun 24;137(25):3507-3517. doi: 10.1182/blood.2020008201.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Griggio V; Vitale C; Coscia M; Salvetti C; Gaidano G; Mauro FR; Foà R; Boccadoro M; Scarfò L; Cuneo A; Tedeschi A; Reda G; Orsucci L; Trentin L; De Paoli L; Montalbano MC; Boccellato E; Perutelli F; Marchetti M; Pennese E; Gentile M; Rivela P; Murru R; Laurenti L; Rigolin GM; Vassallo F; Cassin R; Porrazzo M; Schiattone L; et alii...

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. in Leukemia / Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Sportoletti P; Laurenti L; Gattei V; Gaidano G; Polliack A; Foà R; Rossi D; Cuneo A; Di Raimondo F; Rigolin GM; Bomben R; Biagi A; Del Giudice I; Angeletti I; Rago A; Arrigo G; Vigna E; Botta C; Tripepi G; Fraticelli V; Zucchetto A; Scortechini I; Loseto G; Consoli U; Rossi FM; Pietrasanta D; Murru R; Chiarenza A; Condoluci A; et alii...

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.

2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara

Piciocchi A; Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Nanni M; De Propris MS; Della Starza I; Raponi S; Del Giudice I; Murru R; Ruocco V; Ibatici A; Varettoni M; Laurenti L; Chiarenza A; Zinzani PL; Gentile M; Molinari A; Gozzetti A; Tani M; Musuraca G; Gottardi D; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. in Blood / Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.

2021
AO Cuneo
AOU Alessandria

Guarini A; Mauro FR; Cuneo A; Vignetti M; Peragine N; Mariglia P; Nanni M; Marchetti M; Trentin L; Molica S; Sportoletti P; Reda G; Albano F; Arena V; Piciocchi A; Cafforio L; Ilari C; Raponi S; Cura F; García-Jacobo RE; Foà R; Melandri A; Bardi A; Del Giudice I; Rigolin GM;

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. in Leukemia / Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Ghia P; Stamatopoulos K; Montserrat E; Cuneo A; Foà R; Rambaldi A; Coscia M; Yassin M; Vitale C; van Kampen R; San Segundo LY; Wróbel T; Wasik-Szczepanek E; Varettoni M; Visentin A; Trentin L; Van Der Spek E; van Gelder M; Te Raa D; Tonino SH; Tadmor T; Stavroyianni N; Stanca O; Sportoletti P; Šimkovi? M; Špa?ek M; Shrestha A; Saghumyan G; Reda G; et alii...

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Ferrarini M; Foà R; Polliack A; Trentin L; Cuneo A; Gaidano G; Di Raimondo F; Rossi D; Olivieri J; Jaksic O; Bomben R; Neri A; Fronza G; Rago A; Angeletti I; Cutrona G; Del Giudice I; Biagi A; Galimberti S; D'Arrigo G; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; Zucchetto A; Rossi FM; Recchia AG; et alii...

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

D Arrigo G; Murru R; Gentile M; Gattei V; Polliack A; Trentin L; Gaidano G; Di Raimondo F; Cuneo A; Cutrona G; Rossi D; Menichini P; Olivieri J; Fronza G; Monti P; Del Giudice I; Bomben R; Neri A; Angeletti I; Biagi A; Rago A; Martino EA; Cassin R; Galimberti S; Foà R; Ferrarini M; Scortechini I; Rossi FM; Zucchetto A; et alii...

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. in Hematological oncology / Hematol Oncol. 2021 Aug;39(3):326-335. doi: 10.1002/hon.2861. Epub 2021 Mar 26.

2021
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Cuneo A; Foà R; Marchetti M; Gentile M; Vignetti M; Mauro FR; Crea E; Marasca R; Laurenti L; Molinari AL; Pietrasanta D; Quaglia FM; Sportoletti P; Paolini R; Varettoni M; Gaidano G; Murru R; Vitagliano O; Coscia M; Farina L; Cibien F; Zamprogna G; Arena V; Visentin A; Reda G; Cavazzini F; Piciocchi A; Montillo M; Rigolin GM; et alii...

Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. in European journal of haematology / Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Ferrarini M; Foà R; Trentin L; Polliack A; Gaidano G; Cuneo A; Di Raimondo F; Rossi D; Jaksic O; Monti P; Cutrona G; Bomben R; Neri A; Fronza G; Menichini P; Biagi A; Del Giudice I; Angeletti I; Rago A; Galimberti S; Cassin R; D'Arrigo G; Mendicino F; Martino EA; Vigna E; Al-Janazreh H; Zucchetto A; et alii...

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. in Frontiers in oncology / Front Oncol. 2021 Apr 15;11:637186. doi: 10.3389/fonc.2021.637186. eCollection 2021.

2021
AO Cuneo

Puzzolo MC; Del Giudice I; Peragine N; Mariglia P; De Propris MS; Cappelli LV; Trentin L; Reda G; Cuneo A; Molica S; Piciocchi A; Arena V; Mauro FR; Guarini A; Foà R;

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. in Blood cancer journal / Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3.

2020
AOU Città della Salute di Torino
AO Cuneo
AOU Alessandria
AOU Novara

Gattei V; Morabito F; Ferrarini M; Gaidano G; Cuneo A; Foà R; Trentin L; Fronza G; Cutrona G; Di Raimondo F; Angeletti I; Bomben R; Neri A; D'Arrigo G; Tripepi G; Vitale C; Al-Janazreh H; Rossi FM; Zucchetto A; Scortechini I; Consoli U; Loseto G; Pietrasanta D; Bossio S; Moia R; Recchia AG; Lucia E; Mendicino F; Vigna E; et alii...

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. in Leukemia / Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.

2020
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Foà R; Rambaldi A; Montserrat E; Rossi G; Stamatopoulos K; Coscia M; Stavroyianni N; Strugov V; Tam C; Zdrenghea M; Shah N; Shrestha A; Stanca O; Ortiz Pareja M; Papaioannou M; Rossi D; Kalashnikova O; Hakobyan Y; Doubek M; Enrico A; Dimou M; Andres M; Chiarenza A; Nikitin E; Dos Santos G; Barna G; Yassin M; Pocali B; Sportoletti P; et alii...

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). in Haematologica / Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705.

2020
AOU Città della Salute di Torino
AO Cuneo
AOU Alessandria

Foà R; Guarini AR; Raponi S; De Propris MS; Della Starza I; Del Giudice I; Albano F; Cuneo A; Neri A; Piciocchi A; Vignetti M; Nanni M; Musolino C; Battistini R; Del Poeta G; Pietrasanta D; Gozzetti A; Liberati AM; Reda G; Tedeschi A; Re F; Soddu S; Mauro FR; Angelucci E; Zaja F; Coscia M; Ilariucci F; Molica S;

A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. in Hematological oncology / Hematol Oncol. 2019 Oct;37(4):508-512. doi: 10.1002/hon.2655. Epub 2019 Aug 5.

2019
AOU Città della Salute di Torino
AO Cuneo

Semenzato G; Trentin L; Foà R; Cuneo A; Coscia M; Cassin R; Laurenti L; Tedeschi A; Cesini L; Piazza F; Rigolin GM; Molica S; Vitale C; Reda G; Autore F; Mauro FR; Deodato M; Visentin A;

Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. in British journal of haematology / Br J Haematol. 2019 Oct;187(1):e8-e11. doi: 10.1111/bjh.16123. Epub 2019 Jul 31.

2019
AOU Città della Salute di Torino
AO Cuneo

Laurenti L; Foà R; Cuneo A; Scarfò L; Tedeschi A; Efremov DG; D'Arena G; Gentile M; Levato L; Murru R; Sportoletti P; Coscia M; Ciolli S; Ibatici A; Reda G; Rigolin GM; Del Poeta G; Trentin L; Schiattone L; Mauro FR; Frustaci A; Piciocchi A; Autore F; Morelli F; Innocenti I;

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. in Cancers / Cancers (Basel). 2019 Jun 26;11(7):896. doi: 10.3390/cancers11070896.

2019
AOU Città della Salute di Torino
AO Cuneo

Laurenti L; Ferrajoli A; Foà R; Sica S; Visentin A; Reda G; Tisi MC; Vitale C; Rigolin GM; Ferretti A; Efremov DG; Vincelli D; Murru R; D'Arena G; Falcucci P; Molica S; Morabito F; Gentile M; Frustaci AM; Mauro FR; Gozzetti A; Cuneo A; Visco C; Coscia M; Cortelezzi A; Trentin L; Corrente F; Innocenti I; Strati P; et alii...

A MRD-guided approach for the combination of ibrutinib to venetoclax in relapsed/refractory patients with chronic lymphocytic leukemia (improve study) in Hematological Oncology

2017
AO Cuneo
AOU Città della Salute di Torino

Ghia P; Scarfò L; Coscia M; Sancetta R; Ferrario A; Tedeschi A; Farina L; Laurenti L; Orlandi E; Reda G; Motta M; Carlo Stella C; Massaia M; Quaresmini G; Rossini F; Ladetto M; Gaidano G; Rossi V; Montillo M; Chiappella A; Carniti C; Ceccarelli M; Cabras MG; Re A; Salvi F; Santoro A; Stefoni V; Pileri S; Ciccone G; et alii...